Tyra Biosciences shares drop after clinical trial adverse events reported
Tyra Biosciences shares fell 23% to $20.50 after the company said some patients in a mid-stage bladder-cancer treatment trial reported side effects including fatigue, diarrhea and dry eyes.
Shares of Tyra Biosciences fell after the company said some patients in a mid-stage trial of its treatment for certain types of bladder cancer reported side effects including fatigue, diarrhea and dry eyes. 50 shortly after W…